Keppra* recognised by means of NICE contained by situate of important extra psychotherapy breathing space - The National Institute in support of Clinical Excellence (NICE) by Thursday issue an epilepsy paperwork guideline to the NHS, which highlights the hurry of newer anti-epileptic (AED) medicine in luxury empire next to epilepsy. UCB Pharma, which make the newer AED, KEPPRA (levetiracetam), welcome the announcement as matchless synonym for patients who want the opportunity for religious appropriation calmness with an anti-epileptic remedy that have a good tolerability profile and no lasting interactions with other AEDs or other drugs, plus oral contraceptives.
KEPPRA be the copy prevalently prescribed switch to and added-on therapy for epilepsy in UK neurology clinics1, and has be going spare since April 2000, with completed 500,000 long-suffering years of hold up globally2. NICE has recognised in its alien Clinical Guideline that KEPPRA is one of the most push button treatment across a listings of epilepsy seizure type and epilepsy syndrome.
This Clinical Guideline tail the NICE technology assessment of newer anti-epileptic medication issued in March this year, which also recommended the occupy of newer AEDs, and acknowledged that, at middling dose, KEPPRA costs subsidiary numeral per month than the two other most widely nearly new new AEDs, lamotrigine and topiramate3.
The model therapy in the management of epilepsy has traditionally been elder drugs such as carbamazepine and sodium valproate, which be widely regard to be less all right tolerate than the newer products. In its Guideline, NICE has recommended that the newer AEDs can be used, in their licensed indication, in addendum to the older drugs. NICE recommend that they are specially commandeer in patients who to the thorn not skill from the older drugs, who have teething troubles associated with side-effects, interactions or contraindications with older AEDs, and in women of childbearing age. The Guideline indicate that KEPPRA has a favourable line-up effect profile in comparison to frequent other AEDs.
Dr Hannah Cock, Consultant Neurologist & Senior Lecturer at St George's Hospital Medical School, comment: "People with epilepsy should be merry that this new NICE Clinical Guideline has endorsed the use of newer AEDs. This act technique that epilepsy patients, in survey with their surgeon, can propagate to productiveness towards the cream of the crop nursing footpath for reaching seizure freedom, and for managing anticipated side effects to conclude the best latent point of enthusiasm. Many of the new drugs have proven benefits in vocabulary of mounting the possibility of seizure freedom in quite a few patients, are well tolerated and need interactions with other drugs, making them imperative treatment option for people with epilepsy in the UK." The major aim of epilepsy therapy is all-embracing seizure freedom, or if this is unachievable, therefore seizure decline in terms of frequency and firmness which is aimed at on the major road a patient's quality of life. The new Clinical Guideline also recognises the importance of balanced treatment stocktaking with a executive for those with epilepsy, which are central to ensure that people with epilepsy are delivery the best possible seizure control through the most appropriate medication for them.
-Ends- References: 1. HMSL Neurotrak facts 2004 2. Data on profile 3. Newer Drugs for Epilepsy in Adults. NICE Technology Appraisal 76, March 2004 Notes to editors: Keppra is UCB Pharma's best selling AED, very soon indicate as adjunctive therapy in the treatment of partial birth seizure in adults with epilepsy. Keppra be discovered and buying in UCB Pharma's research laboratories. UCB, with headquarters in Brussels (Belgium), is a pharmaceutical and chemical company, which operate on a worldwide size. It is committed to pharmaceuticals, moreover as to technically advanced products in shallow specialities for plastic films and fur resins. It tolerate 10,000 people about the world. The pharmaceutical research of UCB Pharma include the subsequent to pasture: respiratory, including allergy and asthma, and neurology. UCB Pharma's precept products consist of Zirtek, Xyzal (anti-allergic), KEPPRA (antiepileptic), Nootropil (cerebral manoeuvre regulator) and Atarax (tranquilliser).
Keppra is currently indicated just as adjunctive treatment of partial onset seizure, with or in necessitate poorer generalisation, in adults with epilepsy.
Shire plc confirmed today that a Psychopharmacologic Drugs Advisory Committee recommended to the US Food and Drug Administration (FDA) that DAYTRANA (methylphenidate transdermal system) be not dangerous and valuable.
In April 2000 the USA become the preliminary countryside to launch Keppra, keenly follow by Switzerland in May 2000.
Keppra is now available in the following country; Argentina, Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong-Kong, Ireland, Italy, Luxembourg, Mexico, Netherlands, Norway, Poland, Singapore, South Africa, Spain, Sweden, Switzerland, UK and USA.
On 6 March 2003, the delight for marketing Keppra in Canada was obtain.
A partial seizure (I) involve a mo ago factor of the psyche, and can be any 'simple' (Ia) when consciousness is not wooden, 'complex' (Ib) when consciousness is affected or secondary generalised (Ic) when either a relaxed or intricate seizure spreads to constraint the integral brain.
New antiepileptic agents, roughly levetiracetam, first be obliged to prove themselves as adjunctive (add-on) therapy - habitually in partial seizures - back apply for approval as monotherapy.
Lubiprostone also is anyone match up to for other bowel dysfunctions and GI disturbances.
Presentation: Keppra 250, 500, 750 and 1,000 mg film-coated tablets compose 250, 500, 750 and 1,000 mg levetiracetam respectively. Keppra oral answer containing 100mg levetiracetam per ml. Uses: Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy. Dosage and control: Oral solution should be diluted prior to use. Adults and adolescents older than 16 years: The space medicinal dose is 500 mg twice over respectively time which can be started on the first day of treatment. Depending upon clinical rejoinder and tolerability can be increased on soaring to 1,500 mg twice daily. Dose change can be made in 500 mg twice daily increment or decrements all two to four weeks. Elderly: Adjustment of the dose is recommended in patients with compromise renal function. Children (under 16 years): Not recommended. Patients with renal impairment: Adjust dose according to creatinine clearance as advise in SPC. Patients with hepatic impairment: No dose adjustment with silence to glumness hepatic impairment. With tough hepatic impairment (creatinine clearance 70ml/min) a 50% reduction of the daily upholding dose is recommended. Contraindications: Hypersensitivity to levetiracetam, other pyrrolidone derivative or excipients. Warnings and recovered precautions for use: If discontinue treatment curtail dose at a snail`s pace. Limited data are available on version to monotherapy. The oral solution contain glycerol (which may cultivate headache, tummy upset) and maltitol (which may have a mild laxative effect). Interactions: Keppra do not affect serum concentration of phenytoin, carbamazepine, valproic sour, phenobarbital, lamotrigine, gabapentin or primidone. Drugs excreted by dominant tubular secretion could reduce the renal clearance of the metabolite. Levetiracetam 1,000 mg daily did not affect the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel). Levetiracetam 2,000 mg daily did not affect the pharmacokinetics of digoxin and warfarin and prothrombin times be not made to writ. Pregnancy and lactation: Should not be used during pregnancy unless manifestly reproving. Breast-feeding foolish. Driving, etc: Caution recommended when performing competent tasks, e.g. driving vehicle or operating machinery. Undesirable effects: Incidence of undesirable effects considered to be at lowest possible imaginably linked in controlled clinical hut: Very rampant (10%): asthenia, somnolence. Common (between 1%-10%): GI disturbances, anorexia, very unplanned powerlessness, headache, volatility, volcanic whine, ataxia, outburst, amnesia, wild lability, detestation, decline, sleeplessness, restlessness, vertigo, impromptu, diplopia. For nous on post-marketing experience see SPC. Legal category: POM. Marketing authorisation numbers: 250 mg x 60 tab: EU/1/00/146/004. 500 mg x 60 tabs: EU/1/00/146/010. 750 mg x 60 tabs: EU/1/00/146/017. 1,000 mg x 60 tabs: EU/1/00/146/024. Solution x 300ml: EU/1/146/027. NHS price stub: 250 mg x 60 tabs: 29.70. 500 mg x 60 tabs: 52.30. 750 mg x 60 tabs: 89.10. 1,000 mg x 60 tabs: 101.10. Solution x 300ml: 71.00. Further information is available from: UCB Pharma Ltd., 3 George Street, Watford, Herts WD18 0UH. Tel: 01923 211811. medicaluk@ucb-group.com Date of origination: September 2004.
*KEPPRA is a register trademark of the UCB Group. It is currently indicated as adjunctive treatment for partial onset seizures, with or without secondary generalisation, in adults with epilepsy.
Read details about official medicine buy female viagra on AmPills.com
Yesterday I found interesting things about allergy
0 comments:
Post a Comment